Report Highlights

U.S. Sleeping Bruxism Treatment: Market Overview

The U.S. sleeping bruxism treatment market is a dentistry-led segment within the broader sleep and oral health economy, valued at USD 1.12 billion in 2024. Unlike global markets where pharmacological or surgical options lead, American demand is driven by custom occlusal splints dispensed through general and prosthodontic practices. Sleep bruxism affects a substantial share of adults, yet most cases remain undiagnosed because patients present with tooth wear, jaw pain, or headaches rather than sleep complaints.

Structurally, the market differs from the global norm in its reimbursement dependence. Dental benefit plans typically classify splints under coded occlusal orthotic services, while medical coverage rarely applies. Consequently, out-of-pocket spending dominates, and practice-level pricing rather than payer contracts determines margin. Growth is steady rather than explosive, with a forecast CAGR of 6.5% reflecting gradual awareness gains rather than new therapeutic breakthroughs.

Growth Drivers in Sleeping Bruxism Treatment in the U.S.

First, an aging population and rising sleep-disorder screening are expanding the diagnosable pool. Dentists increasingly screen for nocturnal grinding during routine examinations, and the International Classification of Sleep Disorders, which the American Academy of Sleep Medicine maintains, recognizes sleep bruxism as a distinct condition. ICD-10-CM code G47.63 supports medical-necessity documentation, which strengthens claims for appliances that dental plans might otherwise deny.

Second, digital dentistry is lowering the cost and turnaround of custom appliances. Intraoral scanners from Align Technology and Dentsply Sirona allow practices to send files to in-house milling or 3D-printing labs, cutting delivery from weeks to days. Demand from dental sleep medicine practices that integrate home sleep apnea testing further broadens patient flow into bruxism care.

Market Restraints and Entry Barriers

The most consequential barrier is reimbursement fragmentation. Traditional Medicare Part B does not generally cover oral appliances for bruxism, and most private dental benefit carriers apply frequency limits, often one replacement splint every three to five years. Entrants must design products that qualify under specific dental procedure codes, notably D7880 for occlusal orthotic devices, while maintaining cash-pay pricing for uncovered cases.

Regulatory and incumbent barriers add further friction. Custom intraoral splints fall under FDA classification 21 CFR 872.5570, so new designs require 510(k) clearance, and state dental practice acts limit who may dispense or adjust them. Established laboratories such as Glidewell Dental hold dense dentist referral networks, while direct-to-consumer mouthguard sellers undercut prescription appliances on price.

Market Opportunities in the U.S. Sleeping Bruxism Treatment Market

The nearest opportunity lies in dental sleep medicine integration. Practices credentialed through the American Academy of Dental Sleep Medicine represent the highest-value channel for appliances that document compliance. Sensor-enabled splints that log grinding events and jaw-muscle activity would give these clinics payer-ready records, and we estimate the addressable U.S. market for adherence-monitored appliances at USD 310 million by 2028.

A second opportunity is cash-pay fulfilment through remote dentistry. Licensed dentists can already use digital scan workflows, subject to state-by-state telehealth rules, to prescribe appliances after an initial in-person examination. Entrants offering 3D-printed splints shipped within seven days could capture an estimated USD 180 million cash-pay segment currently served by fragmented local laboratories.

Market at a Glance

Leading Market Participants

• Dentsply Sirona
• Glidewell Dental
• Align Technology
• Henry Schein
• Patterson Companies
• AbbVie
• ProSomnus
• Vivos Therapeutics
• SomnoMed
• Great Lakes Dental Technologies

Regulatory and Policy Environment

The FDA regulates custom intraoral splints as Class II devices under 21 CFR 872.5570. Manufacturers must obtain 510(k) clearance before marketing a new appliance design, with FDA review averaging about 90 review days before any additional information requests. Drug-based treatment follows FDA labeling, and AbbVie's Botox is approved for chronic migraine and cervical dystonia but not bruxism, so injections are prescribed off-label.

Dental practice is licensed by state boards under state dental practice acts, and the American Dental Association's CDT code set governs claim submission. Sensor-equipped appliances that transmit patient data fall under cybersecurity requirements in Section 524B of the Federal Food, Drug, and Cosmetic Act, alongside HIPAA. No federal subsidy targets bruxism, though the National Institute of Dental and Craniofacial Research funds orofacial pain research within an annual budget exceeding USD 500 million.

Long-Term Outlook for Sleeping Bruxism Treatment in the U.S.

By 2032, the U.S. market is forecast to reach USD 1.85 billion, growing at a 6.5% CAGR from the 2025 base year. Growth will shift from analogue custom splints toward digitally fabricated, sensor-equipped appliances, with adherence data becoming a condition of dental benefit reimbursement. Dental sleep medicine practices will consolidate volume, and mid-sized laboratories without digital workflows will struggle to remain viable.

Competition will concentrate around three models: dental-office distribution through Henry Schein and Patterson Companies, laboratory-led supply from Glidewell Dental, and digital-first oral appliance companies such as ProSomnus and Vivos Therapeutics. Pharmacological therapy will remain a niche adjunct rather than a substitute. Entrants that secure coding recognition and sensor validation by 2028 will hold the most durable positions.